177 related articles for article (PubMed ID: 23447643)
41. Biophysical characteristics of a new mutation on the KCNQ1 potassium channel (L251P) causing long QT syndrome.
Deschênes D; Acharfi S; Pouliot V; Hegele R; Krahn A; Daleau P; Chahine M
Can J Physiol Pharmacol; 2003 Feb; 81(2):129-34. PubMed ID: 12710526
[TBL] [Abstract][Full Text] [Related]
42. Clinical and electrophysiological characterization of a novel mutation (F193L) in the KCNQ1 gene associated with long QT syndrome.
Yamaguchi M; Shimizu M; Ino H; Terai H; Hayashi K; Mabuchi H; Hoshi N; Higashida H
Clin Sci (Lond); 2003 Apr; 104(4):377-82. PubMed ID: 12653681
[TBL] [Abstract][Full Text] [Related]
43. Localization of a functional autoimmune epitope on the muscarinic acetylcholine receptor-2 in patients with idiopathic dilated cardiomyopathy.
Fu LX; Magnusson Y; Bergh CH; Liljeqvist JA; Waagstein F; Hjalmarson A; Hoebeke J
J Clin Invest; 1993 May; 91(5):1964-8. PubMed ID: 7683693
[TBL] [Abstract][Full Text] [Related]
44. Dominant-negative control of cAMP-dependent IKs upregulation in human long-QT syndrome type 1.
Heijman J; Spätjens RL; Seyen SR; Lentink V; Kuijpers HJ; Boulet IR; de Windt LJ; David M; Volders PG
Circ Res; 2012 Jan; 110(2):211-9. PubMed ID: 22095730
[TBL] [Abstract][Full Text] [Related]
45. Galantamine (Reminyl) delays cardiac ventricular repolarization and prolongs the QT interval by blocking the HERG current.
Vigneault P; Bourgault S; Kaddar N; Caillier B; Pilote S; Patoine D; Simard C; Drolet B
Eur J Pharmacol; 2012 Apr; 681(1-3):68-74. PubMed ID: 22366430
[TBL] [Abstract][Full Text] [Related]
46. Modulation of I
An X; Lee J; Kim GH; Kim HJ; Pyo HJ; Kwon I; Cho H
J Cell Physiol; 2022 Jul; 237(7):3069-3079. PubMed ID: 35580065
[TBL] [Abstract][Full Text] [Related]
47. Modulation of functional properties of KCNQ1 channel by association of KCNE1 and KCNE2.
Toyoda F; Ueyama H; Ding WG; Matsuura H
Biochem Biophys Res Commun; 2006 Jun; 344(3):814-20. PubMed ID: 16631607
[TBL] [Abstract][Full Text] [Related]
48. Prospective familial assessment in dilated cardiomyopathy: cardiac autoantibodies predict disease development in asymptomatic relatives.
Caforio AL; Mahon NG; Baig MK; Tona F; Murphy RT; Elliott PM; McKenna WJ
Circulation; 2007 Jan; 115(1):76-83. PubMed ID: 17179019
[TBL] [Abstract][Full Text] [Related]
49. Restricting excessive cardiac action potential and QT prolongation: a vital role for IKs in human ventricular muscle.
Jost N; Virág L; Bitay M; Takács J; Lengyel C; Biliczki P; Nagy Z; Bogáts G; Lathrop DA; Papp JG; Varró A
Circulation; 2005 Sep; 112(10):1392-9. PubMed ID: 16129791
[TBL] [Abstract][Full Text] [Related]
50. Functional effects of a KCNQ1 mutation associated with the long QT syndrome.
Boulet IR; Raes AL; Ottschytsch N; Snyders DJ
Cardiovasc Res; 2006 Jun; 70(3):466-74. PubMed ID: 16564513
[TBL] [Abstract][Full Text] [Related]
51. Clinical implications of anti-heart autoantibodies in myocarditis and dilated cardiomyopathy.
Caforio AL; Tona F; Bottaro S; Vinci A; Dequal G; Daliento L; Thiene G; Iliceto S
Autoimmunity; 2008 Feb; 41(1):35-45. PubMed ID: 18176863
[TBL] [Abstract][Full Text] [Related]
52. Autoantibodies against ADP/ATP carrier from patients with dilated cardiomyopathy increase activity of voltage-dependent Ca channels in isolated cardiac myocytes.
Liao YH; Cheng LX; Dai SP; Tu YS
Blood Press Suppl; 1996; 3():41-4. PubMed ID: 8973768
[TBL] [Abstract][Full Text] [Related]
53. Novel KCNE3 mutation reduces repolarizing potassium current and associated with long QT syndrome.
Ohno S; Toyoda F; Zankov DP; Yoshida H; Makiyama T; Tsuji K; Honda T; Obayashi K; Ueyama H; Shimizu W; Miyamoto Y; Kamakura S; Matsuura H; Kita T; Horie M
Hum Mutat; 2009 Apr; 30(4):557-63. PubMed ID: 19306396
[TBL] [Abstract][Full Text] [Related]
54. Recent molecular insights from mutated IKS channels in cardiac arrhythmia.
Dvir M; Peretz A; Haitin Y; Attali B
Curr Opin Pharmacol; 2014 Apr; 15():74-82. PubMed ID: 24721657
[TBL] [Abstract][Full Text] [Related]
55. [Detection of Autoantibodies Against the 1-Adrenergic Receptor in the Sera of Patients via the Competitive cell-Based Enzyme Linked Immunosorbent Assay].
Shevelev AY; Kostiukevich MV; Efremov EE; Vlasik TN; Mironova NA; Zykov KA; Kashirina NM; Kuznetsova IB; Sharf TV; Mamochkina EN; Lipatova LN; Peklo MM; Rutkevich PN; Yanushevskaya EV; Rybalkin IN; Stukalova OV; Malkina TA; Belyaeva MM; Kuznetsova TV; Tkachev GA; Zinchenko LV; Gupalo EM; Agapova OY; Yureneva-Tkhorzhevskaya TV; Rvacheva AV; Sidorova MV; Sadgyan AS; Tereshchenko SN; Golitsyn SP
Kardiologiia; 2016 Dec; 56(11):61-70. PubMed ID: 28290821
[TBL] [Abstract][Full Text] [Related]
56. Probing binding sites and mechanisms of action of an I(Ks) activator by computations and experiments.
Xu Y; Wang Y; Zhang M; Jiang M; Rosenhouse-Dantsker A; Wassenaar T; Tseng GN
Biophys J; 2015 Jan; 108(1):62-75. PubMed ID: 25564853
[TBL] [Abstract][Full Text] [Related]
57. IKs response to protein kinase A-dependent KCNQ1 phosphorylation requires direct interaction with microtubules.
Nicolas CS; Park KH; El Harchi A; Camonis J; Kass RS; Escande D; Mérot J; Loussouarn G; Le Bouffant F; Baró I
Cardiovasc Res; 2008 Aug; 79(3):427-35. PubMed ID: 18390900
[TBL] [Abstract][Full Text] [Related]
58. Polyunsaturated fatty acid-derived I
Skarsfeldt MA; Liin SI; Larsson HP; Bentzen BH
Acta Physiol (Oxf); 2020 Aug; 229(4):e13471. PubMed ID: 32223014
[TBL] [Abstract][Full Text] [Related]
59. In silico investigation of a KCNQ1 mutation associated with short QT syndrome.
Adeniran I; Whittaker DG; El Harchi A; Hancox JC; Zhang H
Sci Rep; 2017 Aug; 7(1):8469. PubMed ID: 28814790
[TBL] [Abstract][Full Text] [Related]
60. Effects of protein-protein interactions and ligand binding on the ion permeation in KCNQ1 potassium channel.
Jalily Hasani H; Ganesan A; Ahmed M; Barakat KH
PLoS One; 2018; 13(2):e0191905. PubMed ID: 29444113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
